DR. ENGLE: An article in Hepatology
1 implied that liver transplants cause a repopulation of the cells so that eventually the primitive host bone marrow cells replace the donor lives cells. Have you found this to be true, and what are its implications?
DR. CHOWDHURY: Were you asking about bone marrow cells giving rise to liver cells? The article in Hepatology described transplanting bone marrow stem cells. After transplantation, they become converted to hepatocytes and gradually repopulate the host liver. That's a completely different issue than how the transplanted liver gets tolerated in the host.
DR. WATCHKO: Dr. Chowdhury, could you expand on your experience with AAV in gene therapy for liver diseases? We have been using AAV as a viral vector in managing or attempting to treat animal models of muscular dystrophy. As with the liver, muscle is a tissue that doesn't undergo increased numbers of muscle cells over time. We have had good success using AAV as a vector in both MDX mouse model for Shands muscular dystrophy and also in the BIO 14.6 hamster as a -rcoglycan-deficient model. I had expected you to sing the praises of AAV as a vector. Why isn't this the case? DR. CHOWDHURY: AAV, at least in the doses and titers that were available to us, has not given results comparable to results with our other vectors such as V40. Perhaps we could achieve the same results with higher and repeated doses. It seems to be a little more effective if given in the muscle than in the liver.
DR. STEVENSON:
We can monitor gene expression in the laboratory so that we can know about efficiency and transfection and persistence. How can we do this in humans? Are there ways to tag these systems? What technologies can we use? How do we reach the next stage of monitoring gene therapies when we won't have to look simply at a gross function but can actually look at the expression of a gene product? Do we have the tools available for that now?
DR. CHOWDHURY: In Crigler-Najjar syndrome, the transplanted or implanted cell could be monitored in various ways. However, all the methods will lead to patchy monitoring at best. For example, if you want to assay from liver biopsy, the result will be extremely random. Therefore, for Crigler-Najjar syndrome, the best way of monitoring would be simply to place a duodenal tube and aspirate a drop of bile for HPLS and determine the ratio of the unconjugated peak to conjugated peak. The better the gene therapy, the shorter the unconjugated and the taller the conjugated peak. For each disease, we would have to devise something imaginative to monitor gene expression.
DR. CONTAG: For exactly that reason, it's important to develop new imaging tools. There are many investigators working in this field of functional imaging or in vivo cellular and molecular imaging. Imaging modalities that have deeper penetration than the optical ones that we spoke about today would be very useful. Single photon emission computed tomography (SPECT) or positron emission tomography (PET), which build reporter genes that concentrate radionuclides, are useful for doing this sort of thing. Then with whole body, three-dimensional scanning, we could get information about the transfer gene or the engineered cell. Reporter genes and systems are being built to tell us about gene expression using magnetic resonance imaging (MRI), but MRI may never have sufficient sensitivity. A variety of technologies are on the horizon to monitor engineered cells or monitor gene transfer, although are not clinically available yet.
DR. BHUTANI: Dr. Vreman, how would you envision looking at heme oxygenase expression? DR. VREMAN: I'm not qualified to look at the heme oxygenase expression because it would be difficult to extract samples from living human beings. However, we could measure the total body carbon monoxide excretion or do end-tidal CO measurements to assess the effectiveness of the metalloporphyrin.
DR. CONTAG: The hope for the gene expression studies is that we will learn in our animal models which of these metalloporphyrins don't affect expression but do affect the protein.
In this regard, Dr. Vreman's assays are extraordinary. It may be that the metalloporphyrins that don't affect transcription in the animal may do so in humans; the functional assay of measuring carbon monoxide is the way to determine that.
DR. JOHNSON: Infants who have excessive jaundice are exposed to what one would think would be excessive levels of CO, and infants with less jaundice would have less. If a metalloporphyrin therapy were directed to those infants in the higher-risk groups, who, in general, are producing more CO and production of bilirubin or CO isn't limited, why would that be 
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harmful after one injection of the metalloporphyrin? Couldn't you monitor the CO level to be sure it was safe? DR. VREMAN: When you measure the CO level, you measure total body CO level. When you administer intravenous metalloporphyrins in animals, it ends up in the liver and spleen first, and then smaller portions go to the kidneys. So measuring total body CO production is not indicative of the effect on these organs. Also, I don't think that CO produced in the liver and spleen is very functional. Phase evaluation is mostly done in the epithelial cells or affected by the endothelial cells' production of CO.
DR. JOHNSON: Are you concerned about the lack of CO as a neurotransmitter, especially from your work suggesting that metalloporphyrins don't enter the brain or don't affect the HO-2.
DR. VREMAN: Yes, I tend to be rather conservative on this. There are no ''magic bullets,'' and we must be careful when we administer compounds that have effects at several different levels. We need to diagnose exactly which children need to receive treatment. Follow-up monitoring would be mandatory, particularly as these young infants are developing organisms and a small change may in time translate to a significant effect later in life.
DR. STARK: Are metalloporphyrins the only class of compounds that inhibit heme oxygenase? DR. VREMAN: No. Maines reported work on peptides. DR. DENNERY: Those peptides were reported by Buelow. The problem is that there is an inhibitory effect of these peptides on heme oxygenase activity, but then when you look at the message for heme oxygenase and the protein, there is up-regulation in the end. This reconfirms the earlier point that the enzyme is somewhat tightly regulated and is not meant to be tampered with. There is always a rebound effect.
DR. STEVENSON: This is one of the reasons we wanted to study the impact of these metalloporphyrins on the genetic machinery. Also, the later reintroduction of medicine or some other challenge to the heme oxygenase system is important to consider. We want to make sure that these challenges to enzymatic systems at different times in development don't have long-term consequences in terms of how that system might respond later. The technologies we have developed will allow us to be more careful about the selection of drugs of this class. If we understand their pharmacokinetics, as well as their other properties, we can choose a drug that is safe, orally absorbable, and least perturbing to the genetic machinery both in and out, and we can determine production rates that would be considered native levels.
DR. CHOWDHURY: Carbon monoxide is a neurotransmitter, but it not only works in the brain, it also controls the blood flow in the lung and liver. I'm glad that you are being so careful and not quickly introducing the drug into the market.
DR. CONTAG: Dr. Watchko, can you elaborate on feto-lipoprotein and ways of increasing the activity that might pump compounds, such as bilirubin, out of the brain.
DR. WATCHKO:
First, I think we must substantiate that bilirubin is a substrate of feto-lipoprotein. The only work we have done is to look at the effects of antenatal dexamethasone on PTP expression in brain epithelial cells. There it does increase expression, but we don't have enough data to draw conclusions.
DR. SHAPIRO:
We have looked in cell culture at the NMDA channel blocker, MK-801, which did not seem to be protective. We have looked in vivo at a few anticonvulsants to see if we can decrease hyperexcitability, but to date this has not been successful. But the concept is sound, and it might be helpful to identify some specific neuroprotectants, as in hypoxia-ischemia.
DR. CHOWDHURY: In terms of pumping bilirubin out of the brain, have you looked at MRP6? It has been shown that when there is cholestasis in liver, the MRP2 expression decreases in the canaliculus, but pigments inside the hepatocyte are pumped out by MRP6. It's not just diffusing out because it is accumulating there; it's actually pumped out. Could such molecules be involved in pumping bilirubin out of the brain?
DR. WATCHKO: MRP2 is a pump for conjugated bilirubin, not for unconjugated bilirubin. The only other transporter that I'm aware of that is expressed in the brain, other than the MDR1 isoform feto-lipoprotein, is MRP1, which is a multidrug-resistant associated protein. MRP1 is expressed not in capillary endothelial cells but on the basolateral surface of the choroid plexus epithelium. MDR1 isoform is expressed on the apical surface of the choroid plexus epithelium, and it is thought that perhaps unconjugated bilirubin in the cerebrospinal fluid can be transported into the choroid plexus, which contains conjugating enzymes. So, theoretically, these enzymes could conjugate bilirubin, which then would be a substrate to be pumped back into the blood.
DR. CHOWDHURY: There is an extremely low level of bilirubin-conjugating enzyme in the choroid plexus; therefore, I don't think that the bilirubin that accumulates in the brain is entirely conjugated bilirubin; in fact, it's unconjugated bilirubin. Has anyone looked at other types of MRP such as the OATP family?
DR. WATCHKO: Within the central nervous system, the only ones I'm aware of are MRP1 and MDR1. I don't believe OATP has been looked at systematically. There is a whole host of transporters, and many have not been identified.
DR. FANAROFF: Gene therapy offers a lot of excitement, but also a lot of frustration in terms of the vector. The viral vectors are not panning out; they are more dangerous than we would like them to be. Are there any other routes that you could take? What about liquid ventilation as a source to introduce something into the body? DR. CHOWDHURY: The only organ for which targeted molecule delivery has been researched in any depth is the liver. Lipoprotein receptor was the first receptor that we saw as a white powder rather than as some kind of a functional thing, so we can target genes to the liver. We don't need to use viral vectors because targeting to the liver has become very powerful. The limiting factor had been that it degraded from the plasma over time. But today, we have new methods by which the plasma can be made to integrate into the cell. On the other hand, just because there has been a death from adenovirus doesn't mean that we have to give up the viruses completely. A total of 0.3% of the human genome is made up of viruses, which is just extraneous DNA that is integrated. Recombinant viruses aren't necessarily to be dreaded, but one has to be careful, as with any other drug.
DR. CONTAG: I agree that the viral vectors have application. We have been doing some work with liquid ventilation delivering viral vectors or naked DNA to the lung, but it has not been extremely successful. Other groups are working with adeno-associated virus and adenovirus. Liposome-mediated delivery of DNA has been somewhat promising.
DR. STEVENSON: We come to the end of a brief but intense journey, and I think we have accomplished a lot through our discussions, which have been greatly enhanced by the multidisciplinary approach. I began this meeting by suggesting to you that most of what we deal with is both genetic and environmental, and that context is important. You can see in many of the presentations a blend of expertise that ranges from the most basic to the whole organism. Similarly, as physicians, when we search for new therapies, we have to pay attention to the fundamental details, beginning with the biology, chemistry, and the physiology, that makes a difference to the person. This conference has been strengthened by people from different disciplines talking to each other, developing a common language, and I think this is extremely important for our future direction.
